Feedback
Settings

Settings

Goto Application

222,337 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 22,234
1.WO/2026/099117PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL
WO - 15.05.2026
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
 Appl.No PCT/EP2025/081670 Applicant MERCK PATENT GMBH Inventor MUELLER, Lena
The present invention relates to pharmaceutical compositions comprising a therapeutic peptide having a molecular weight between 1 kDa and 100 kDa dispersed in an inorganic mesoporous material, said inorganic mesoporous material being in particular mesoporous silica.
2.WO/2026/101292PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NECROTIC ENTERITIS CONTAINING TGF-β1 AND FGF2 GENES OR PROTEINS AS ACTIVE INGREDIENTS
WO - 15.05.2026
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
 Appl.No PCT/KR2025/018215 Applicant POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION Inventor KOH, A Ra
The present invention relates to: a pharmaceutical composition for preventing or treating necrotic enteritis, the pharmaceutical composition containing TGF-β1 and FGF2 genes or proteins as active ingredients; and a pharmaceutical preparation and a health functional food that contain the pharmaceutical composition. According to the present invention, TGF-β1 and FGF2, which are known to increase the expression of the CFTR gene, can be used as novel agents for inducing intestinal maturation in premature infants, and various digestive complications such as necrotic enteritis and intestinal absorption disorders, which are intractable diseases, can be treated through the same.
3.WO/2026/097617RECOMBINANT HIRUDIN WITH TYROSINE SULFATION, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 14/815
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
81Protease inhibitors
815from leeches, e.g. hirudin, eglin
 Appl.No PCT/CN2024/133290 Applicant WUHAN YUANQI HE SHENG TECHNOLOGIAE SOCIETAS LIMITATA Inventor XING, Junqiao
The present invention belongs to the technical field of genetic engineering. Provided are a recombinant hirudin with tyrosine sulfation, a preparation method therefor and the use thereof. In order to improve the safety and synthesis yield of recombinant hirudin, and reduce the production cost, a recombinant hirudin with tyrosine sulfation is prepared by means of an algae expression vector.
4.WO/2026/099147SEMAGLUTIDE IN THE TREATMENT OF INTERMITTENT CLAUDICATION
WO - 15.05.2026
Int.Class A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
 Appl.No PCT/EP2025/081744 Applicant NOVO NORDISK A/S Inventor CATARIG, Andrei-Mircea
Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.
5.WO/2026/099761PEPTIDES
WO - 15.05.2026
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/IB2025/061314 Applicant SALEM, Yahya Ahmed Inventor SALEM, Yahya Ahmed
Provided are polyarginine polypeptide ASIC inhibitors, pharmaceutical compositions comprising the same as well as methods and uses therefor In particular, the present disclosure relates to the methods and uses of such polypeptides or pharmaceutical compositions in the treatment of ASIC-related diseases. Such polypeptides or pharmaceutical compositions are useful to treat neurological disorders, neurodegenerative diseases, psychological disorders, sexual disorders, cardiovascular diseases, respiratory diseases, inflammatory diseases, renal diseases, gastrointestinal diseases, metabolic disorders, cancer, and addiction, e.g. smoking addiction.
6.WO/2026/098717POLYPEPTIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 7/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
02Linear peptides containing at least one abnormal peptide link
 Appl.No PCT/CN2025/134211 Applicant ZHONGSHAN LAIBO RUICHEN BIOMEDICINE CO., LTD. Inventor XU, Anchao
A polypeptide compound, a pharmaceutical composition thereof, and a use thereof. A polypeptide compound, the polypeptide compound having a structural formula (XX). The polypeptide compound exhibits good osteogenic activity in vitro, and has relatively good pharmacokinetic properties, indicating that the polypeptide compound has potential application value in the treatment of osteoporosis.
7.WO/2026/101296EXTRACELLULAR VESICLE DERIVED FROM MITOCHONDRIA-TARGETING GRAM-POSITIVE BACTERIA AND RECOMBINANT GRAM-POSITIVE BACTERIA FOR PREPARING SAME
WO - 15.05.2026
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/KR2025/018225 Applicant HLB GENEX, INC. Inventor PAN, Jae Gu
The present invention relates to Gram-positive bacteria-derived extracellular vesicles (EV) having mitochondria-targeting properties and selectivity, and a use thereof. In addition, the present invention relates to a recombinant Gram-positive bacterium strain having improved extracellular vesicle-producing ability. According to the present invention, Gram-positive bacteria-derived extracellular vesicles can be efficiently produced, and active substances such as proteins and nucleic acids can be selectively delivered to mitochondria.
8.WO/2026/101356METHOD FOR ACTIVATING BRAIN REGULATORY T CELLS FOR AMELIORATING OR TREATING AUTISM
WO - 15.05.2026
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/KR2025/018471 Applicant UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY Inventor KWON, Ho Keun
The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.
9.WO/2026/101401METHODS AND MEANS OF TREATING MENTAL DISORDERS
WO - 15.05.2026
Int.Class A61K 31/568
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
568substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
 Appl.No PCT/NL2025/050570 Applicant IP HELICUS HOLDING B.V. Inventor VAN ROOIJ, Kim
The invention relates to a combination of testosterone and/or a functional analogue thereof and oxytocin and/or a functional analogue thereof for administration to subjects in need thereof for improvement of a cognitive disorder, sexual dysfunction, or mood disorder that can advantageously be applied with Repetitive Transcranial Magnetic Stimulation (rTMS) and/or cognitive training.
10.WO/2026/098581PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR
WO - 15.05.2026
Int.Class C07K 14/605
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
605Glucagons
 Appl.No PCT/CN2025/133145 Applicant SHENZHEN ORALEAD PHARMA CO., LTD. Inventor DOU, Liu
An oral pharmaceutical composition and a preparation method therefor. The oral pharmaceutical composition comprises a pharmaceutically acceptable polypeptide or protein, a complex molecule, a compound containing a nitrogen atom functional group, a medium chain fatty acid or a salt thereof, and N-(8-[2-hydroxybenzoyl]-amino)octanoic acid (NAC) or a salt thereof.
# -